Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing products to address the growing need for the use of radiopharmaceuticals in oncology. It is developing targeted copper theranostics-based on its SAR Technology Platform for the treatment of cancer in children and adults. Its lead radiopharmaceutical products include SARTATE, SAR-Bombesin and SAR-bisPSMA. SARTATE targets somatostatin receptor 2 (SSTR2) expressing cancers, including neuroblastoma and neuroendocrine tumors. SAR-Bombesin targets gastrin-releasing peptide receptor (GRPr) expressing cancers, including prostate cancer and breast cancer. SAR-bisPSMA targets prostate-specific membrane antigen (PSMA) expressing cancers, including prostate cancer. Its SAR Technology platform employs a superior chelator (cage) for copper used in the diagnosis and treatment of a range of cancers. The technology can be employed for targeted cancer therapy.